Department of Neurology, The Mary S Easton Center for Alzheimer's Disease Research at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
J Alzheimers Dis. 2010;19(2):375-88. doi: 10.3233/JAD-2010-1286.
The Mary S. Easton Center for Alzheimer's Disease Research (UCLA-Easton Alzheimer's Center) is committed to the "therapeutic imperative" and is devoted to finding new treatments for Alzheimer's disease (AD) and to developing technologies (biomarkers) to advance that goal. The UCLA-Easton Alzheimer's Center has a continuum of research and research-related activities including basic/foundational studies of peptide interactions; translational studies in transgenic animals and other animal models of AD; clinical research to define the phenotype of AD, characterize familial AD, develop biomarkers, and advance clinical trials; health services and outcomes research; and active education, dissemination, and recruitment activities. The UCLAEaston Alzheimer's Center is supported by the National Institutes on Aging, the State of California, and generous donors who share our commitment to developing new therapies for AD. The naming donor (Jim Easton) provided substantial funds to endow the center and to support projects in AD drug discovery and biomarker development. The Sidell-Kagan Foundation supports the Katherine and Benjamin Kagan Alzheimer's Treatment Development Program, and the Deane F. Johnson Alzheimer's Research Foundation supports the Deane F. Johnson Center for Neurotherapeutics at UCLA. The John Douglas French Alzheimer's Research Foundation provides grants to junior investigators in critical periods of their academic development. The UCLA-Easton Alzheimer's Center partners with community organizations including the Alzheimer's Association California Southland Chapter and the Leeza Gibbons memory Foundation. Collaboration with pharmaceutical companies, biotechnology companies, and device companies is critical to developing new therapeutics for AD and these collaborations are embraced in the mission of the UCLA-Easton Alzheimer's Center. The Center supports excellent senior 3 investigators and serves as an incubator for new scientists, agents, models, technologies and concepts that will significantly influence the future of AD treatment and AD research.
玛丽·S·伊斯顿阿尔茨海默病研究中心（UCLA-Easton 阿尔茨海默病中心）致力于实现“治疗强制性”，致力于寻找治疗阿尔茨海默病（AD）的新疗法，并开发技术（生物标志物）以推进这一目标。UCLA-Easton 阿尔茨海默病中心的研究和研究相关活动具有连续性，包括肽相互作用的基础/基础研究；在转基因动物和其他 AD 动物模型中的转化研究；临床研究以确定 AD 的表型，表征家族性 AD，开发生物标志物并推进临床试验；卫生服务和结果研究；以及积极的教育、传播和招募活动。UCLA-Easton 阿尔茨海默病中心得到了美国国立卫生研究院、加利福尼亚州和慷慨捐赠者的支持，他们与我们一样致力于开发 AD 的新疗法。命名捐赠者（Jim Easton）提供了大量资金，用于为该中心提供资金并支持 AD 药物发现和生物标志物开发项目。Sidell-Kagan 基金会支持 Katherine 和 Benjamin Kagan 阿尔茨海默病治疗开发计划，Deane F. Johnson 阿尔茨海默病研究基金会支持加州大学洛杉矶分校的 Deane F. Johnson 神经治疗中心。John Douglas French 阿尔茨海默病研究基金会为处于学术发展关键时期的初级研究人员提供资助。UCLA-Easton 阿尔茨海默病中心与社区组织合作，包括加利福尼亚南部地区阿尔茨海默病协会和 Leeza Gibbons 记忆基金会。与制药公司、生物技术公司和设备公司的合作对于开发 AD 的新疗法至关重要，这些合作是 UCLA-Easton 阿尔茨海默病中心使命的一部分。该中心支持优秀的高级 3 名研究员，并作为新科学家、代理、模型、技术和概念的孵化器，这些将对 AD 治疗和 AD 研究的未来产生重大影响。
